Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease
- PMID: 2566669
- DOI: 10.1097/00005176-198905000-00018
Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease
Abstract
A case of severe sulfasalazine-induced hepatotoxicity is reported in a 14-year-old girl with Crohn's disease. Fourteen days after beginning sulfasalazine, she developed a systemic reaction characterized by high fever, maculopapular rash, lymphadenopathy, abdominal pain, and malaise, with tender hepatomegaly and elevated liver functions, leukemoid reaction, with eosinophilia, and immune complexes. She responded promptly to high-dose intravenous steroids with complete recovery. This case was compared to the three similar pediatric cases in the literature. The latent period was 11-19 days between sulfasalazine therapy and the onset of high fever, generalized lymphadenopathy, and pruritic maculopapular rash that spared palms and soles and resolved with desquamation. All children had hepatotoxicity indicated by tender hepatomegaly, elevated liver enzymes, and histologic inflammation on liver biopsy. The similarity between these features and those of other sulfa-induced hepatotoxic reactions suggests that the sulfapyridine moiety is the etiologic agent in these hypersensitivity reactions. Those children with circulating immune complexes responded well to steroids. Proper therapy for this rare but severe idiosyncratic reaction includes prompt recognition and discontinuation of sulfasalazine, and high-dose corticosteroid therapy.
Similar articles
-
Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity.Gastroenterology. 1978 Jul;75(1):95-9. Gastroenterology. 1978. PMID: 45581
-
Hepatotoxicity after treatment with sulfasalazine.Postgrad Med. 1986 May 1;79(6):193-4, 197-8. doi: 10.1080/00325481.1986.11699392. Postgrad Med. 1986. PMID: 2871549
-
Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.Am J Gastroenterol. 1992 Aug;87(8):1029-32. Am J Gastroenterol. 1992. PMID: 1353658
-
Sulfasalazine-induced fulminant hepatic failure.J Clin Gastroenterol. 1992 Mar;14(2):132-5. doi: 10.1097/00004836-199203000-00012. J Clin Gastroenterol. 1992. PMID: 1348259 Review.
-
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005. Drug Saf. 1991. PMID: 1676590 Review.
Cited by
-
Effect of Thiol-reducing Agents and Antioxidants on Sulfasalazine-induced Hepatic Injury in Normotermic Recirculating Isolated Perfused Rat Liver.Toxicol Res. 2016 Apr;32(2):133-40. doi: 10.5487/TR.2016.32.2.133. Epub 2016 Apr 30. Toxicol Res. 2016. PMID: 27123164 Free PMC article.
-
The natural plant product sophocarpine ameliorates dextran sodium sulfate-induced colitis in mice by regulating cytokine balance.Int J Colorectal Dis. 2012 May;27(5):575-81. doi: 10.1007/s00384-011-1352-z. Epub 2011 Nov 15. Int J Colorectal Dis. 2012. PMID: 22083209
-
Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.Ann Rheum Dis. 1992 Feb;51(2):275-6. doi: 10.1136/ard.51.2.275. Ann Rheum Dis. 1992. PMID: 1347987 Free PMC article.
-
Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.World J Hepatol. 2015 Nov 28;7(27):2716-28. doi: 10.4254/wjh.v7.i27.2716. World J Hepatol. 2015. PMID: 26644815 Free PMC article. Review.
-
Current therapy of inflammatory bowel disease in children.Paediatr Drugs. 2006;8(5):279-302. doi: 10.2165/00148581-200608050-00002. Paediatr Drugs. 2006. PMID: 17037946 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical